Skip to main content
Equibles
GKOS logo

GKOS · GLAUKOS Corp · Investor Relations

Track GKOS — free

Use GKOS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GKOS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$245.72 -0.31 (-0.13%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$14.55B
Shares
59.20M
Volume · Nov 13 546.55K Avg daily vol (3M) 1.16M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-18 10:00 UTC Jefferies Global Healthcare Conference Conference
2026-12-01 18:30 UTC Piper Sandler Annual Healthcare Conference Conference
2026-12-02 20:00 UTC Citi Global Healthcare Conference Conference

Recent news

Date Headline
2026-11-03 Glaukos Announces Participation in Upcoming Investor Conferences
2026-10-28 Glaukos Announces Third Quarter 2026 Financial Results
2026-10-09 Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
2026-10-08 Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
2026-10-07 Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
2026-10-07 Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
2026-09-23 Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
2026-08-19 Glaukos Announces Participation in Wells Fargo Healthcare Conference
2026-07-29 Glaukos Announces Second Quarter 2026 Financial Results
2026-07-27 Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
2026-07-08 Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
2026-06-25 Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
2026-05-12 Glaukos Announces Participation in Upcoming Investor Conferences
2026-04-29 Glaukos Announces First Quarter 2026 Financial Results
2026-04-16 Glaukos Announces the Release of its 2025 Sustainability Report
2026-04-15 Glaukos Receives Permanent J-code for Epioxa™
2026-04-08 Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
2026-04-06 Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
2026-03-19 Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
2026-02-17 Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
2026-01-28 Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
2026-01-20 Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
2026-01-13 Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $143 million, a reported increase of 36% compared to the same period in 2024, consisting of approximately $86 million in U.S. Glaucoma net sales, including iDose® TR net sales of approximately $45 million, approximately $33 million in International Glaucoma net sales, and approximately $24 million in Corneal Health net sales. Preliminary and unaudited total net sales for the full year of 2025 are expected to be approximately $507 million, a reported increase of 32% compared to the full year of 2024, consisting of approximately $299

Past events

Date Event Type
2026-11-10 Stifel Healthcare Conference Conference
2026-10-28 Glaukos' Third Quarter 2026 Financial Results Conference Call Earnings call
2026-09-09 Wells Fargo Healthcare Conference Conference
2026-07-29 Glaukos' Second Quarter 2026 Financial Results Conference Call Earnings call
2026-06-16 Truist MedTech Conference Conference
2026-06-03 Jefferies Global Healthcare Conference Conference
2026-06-02 William Blair Growth Stock Conference Conference
2026-05-26 Stifel Virtual Ophthalmology Forum Event
2026-04-29 Glaukos' First Quarter 2026 Financial Results Conference Call Earnings call
2026-02-17 Glaukos' Fourth Quarter 2025 Financial Results Conference Call Earnings call
2026-01-14 J.P. Morgan Healthcare Conference Conference
2025-12-03 Citi Global Healthcare Conference Conference
2025-11-18 Stephens Annual Investment Conference Conference
2025-11-12 Stifel Healthcare Conference Conference
2025-11-11 UBS Global Healthcare Conference Conference
2025-10-29 Glaukos' Third Quarter 2025 Financial Results Conference Call Earnings call
2025-09-03 Wells Fargo Healthcare Conference Conference
2025-07-30 Glaukos' Second Quarter 2025 Financial Results Conference Call Earnings call
2025-06-04 Jefferies Global Healthcare Conference Conference
2025-06-03 William Blair Growth Stock Conference Conference
2025-05-27 Stifel Virtual Ophthalmology Forum Event
2025-04-30 Glaukos' First Quarter 2025 Financial Results Conference Call Earnings call
2025-02-20 Glaukos' Fourth Quarter and Full Year 2024 Financial Results Conference Call Earnings call
2025-01-15 J.P. Morgan Healthcare Conference Conference
2024-12-05 Citi Global Healthcare Conference Conference

Source: https://investors.glaukos.com/overview/default.aspx

Key facts CIK 1192448 CUSIP 377322102 13F (30d) 331 filings 301 filers Visit website Investor relations